IFG Advisory LLC Buys Shares of 2,072 Madrigal Pharmaceuticals Inc (MDGL)

IFG Advisory LLC bought a new stake in shares of Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 2,072 shares of the biopharmaceutical company’s stock, valued at approximately $443,000.

Other large investors also recently added to or reduced their stakes in the company. WINTON GROUP Ltd boosted its stake in shares of Madrigal Pharmaceuticals by 118.2% in the 3rd quarter. WINTON GROUP Ltd now owns 3,216 shares of the biopharmaceutical company’s stock valued at $689,000 after purchasing an additional 1,742 shares during the last quarter. Wells Fargo & Company MN boosted its stake in shares of Madrigal Pharmaceuticals by 36.9% in the 3rd quarter. Wells Fargo & Company MN now owns 13,749 shares of the biopharmaceutical company’s stock valued at $2,944,000 after purchasing an additional 3,709 shares during the last quarter. Victory Capital Management Inc. boosted its stake in shares of Madrigal Pharmaceuticals by 5.1% in the 3rd quarter. Victory Capital Management Inc. now owns 193,698 shares of the biopharmaceutical company’s stock valued at $41,476,000 after purchasing an additional 9,451 shares during the last quarter. Moody Aldrich Partners LLC boosted its stake in shares of Madrigal Pharmaceuticals by 106.4% in the 3rd quarter. Moody Aldrich Partners LLC now owns 10,467 shares of the biopharmaceutical company’s stock valued at $2,241,000 after purchasing an additional 5,395 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System boosted its stake in shares of Madrigal Pharmaceuticals by 22.4% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 2,572 shares of the biopharmaceutical company’s stock valued at $551,000 after purchasing an additional 470 shares during the last quarter. Hedge funds and other institutional investors own 53.06% of the company’s stock.

MDGL has been the topic of several recent research reports. Zacks Investment Research raised shares of Madrigal Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, July 24th. BidaskClub lowered shares of Madrigal Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Tuesday, October 9th. Goldman Sachs Group lowered shares of Madrigal Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $314.00 target price on the stock. in a research note on Monday, August 6th. Citigroup initiated coverage on shares of Madrigal Pharmaceuticals in a research note on Tuesday, September 4th. They issued a “buy” rating and a $340.00 target price on the stock. Finally, Oppenheimer set a $300.00 target price on shares of Madrigal Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 8th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and seven have assigned a buy rating to the company’s stock. Madrigal Pharmaceuticals has a consensus rating of “Hold” and an average target price of $314.00.

Shares of NASDAQ:MDGL opened at $184.49 on Friday. Madrigal Pharmaceuticals Inc has a fifty-two week low of $38.82 and a fifty-two week high of $325.98.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last announced its quarterly earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.03). On average, research analysts forecast that Madrigal Pharmaceuticals Inc will post -2.25 EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another website, it was illegally stolen and reposted in violation of United States & international copyright law. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/11/10/ifg-advisory-llc-buys-shares-of-2072-madrigal-pharmaceuticals-inc-mdgl.html.

Madrigal Pharmaceuticals Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia.

Featured Story: Technical Analysis of Stocks, How Can It Help

Institutional Ownership by Quarter for Madrigal Pharmaceuticals (NASDAQ:MDGL)

Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply